Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
About 19 months ago we reported that a company called Progenics Pharmaceuticals had acquired all rights to a small, radiolabeled molecule known as [99mTc]MIP-1404, and that an international, multi-center Phase II trial was investigating the clinical activity of [99mTc]MIP-1404 as a prostate cancer imaging agent. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: detection, Diagnosis, imaging, MIP-1404, prognosis | Leave a comment »
According to a media release issued today by Progenics Pharmaceuticals, early clinical studies of two of their investigational products — the imaging agents [123I]-MIP-1072 and [123I]-MIP-1095 — suggest potential of these two agents in enhancement of imaging techniques to identify the exact location of cancer in bone, tissue, and the prostate itself. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: agent, imaging, MIP-1072, MIP-1095, MIP-1404 | Leave a comment »
